Yungjin Pharm. Co., Ltd. (KRX: 003520)
South Korea
· Delayed Price · Currency is KRW 2,365.00
+35.00 (1.50%)
Oct 8, 2024, 3:30 PM KST
Yungjin Pharm. Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 | 2007 - 2003 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '13 Sep 30, 2013 | Dec '12 Dec 31, 2012 | Dec '11 Dec 31, 2011 | Dec '10 Dec 31, 2010 | Dec '09 Dec 31, 2009 | Dec '08 Dec 31, 2008 | 2007 - 2003 |
| Revenue | 158,787 | 137,688 | 112,105 | 116,317 | 103,376 | 110,911 | Upgrade
|
| Revenue Growth (YoY) | 23.36% | 22.82% | -3.62% | 12.52% | -6.79% | 1.14% | Upgrade
|
| Cost of Revenue | 99,504 | 89,299 | 67,382 | - | 60,775 | 62,489 | Upgrade
|
| Gross Profit | 59,284 | 48,389 | 44,724 | 116,317 | 42,601 | 48,422 | Upgrade
|
| Selling, General & Admin | 49,440 | 45,121 | 41,271 | - | 43,942 | 43,236 | Upgrade
|
| Other Operating Expenses | - | - | -633.22 | 115,913 | -693.66 | 4,778 | Upgrade
|
| Operating Expenses | 49,440 | 45,121 | 40,638 | 115,913 | 43,249 | 48,013 | Upgrade
|
| Operating Income | 9,843 | 3,268 | 4,086 | 404.44 | -647.14 | 408.44 | Upgrade
|
| Interest Expense | -1,241 | -1,388 | -1,048 | - | -2,860 | -2,968 | Upgrade
|
| Interest & Investment Income | 284.76 | 42.79 | 155.86 | - | 13.17 | 68.22 | Upgrade
|
| Currency Exchange Gain (Loss) | -631.17 | -631.17 | - | - | -114.03 | 377.24 | Upgrade
|
| Other Non Operating Income (Expenses) | 919.87 | 1,295 | - | -2,216 | - | - | Upgrade
|
| EBT Excluding Unusual Items | 9,176 | 2,586 | 3,193 | -1,812 | -3,608 | -2,114 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | -3.8 | Upgrade
|
| Gain (Loss) on Sale of Assets | 11.71 | 11.71 | - | - | -83.16 | 966.8 | Upgrade
|
| Asset Writedown | - | - | - | - | -656.64 | - | Upgrade
|
| Legal Settlements | - | - | - | - | - | 364.03 | Upgrade
|
| Pretax Income | 9,187 | 2,598 | 3,193 | -1,812 | -4,348 | -787.27 | Upgrade
|
| Income Tax Expense | 659.02 | 803.92 | 612.39 | 497.09 | - | 5,059 | Upgrade
|
| Net Income | 8,528 | 1,794 | 2,581 | -2,309 | -4,348 | -5,846 | Upgrade
|
| Net Income to Common | 8,528 | 1,794 | 2,581 | -2,309 | -4,348 | -5,846 | Upgrade
|
| Net Income Growth | 1006.93% | -30.48% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 159 | 179 | 172 | - | 118 | 118 | Upgrade
|
| Shares Outstanding (Diluted) | 159 | 179 | 172 | - | 118 | 118 | Upgrade
|
| Shares Change (YoY) | -14.83% | 4.28% | - | - | - | 19.10% | Upgrade
|
| EPS (Basic) | 53.49 | 10.00 | 15.00 | - | -36.76 | -49.42 | Upgrade
|
| EPS (Diluted) | 53.49 | 10.00 | 15.00 | - | -36.76 | -49.42 | Upgrade
|
| EPS Growth | 1199.63% | -33.33% | - | - | - | - | Upgrade
|
| Free Cash Flow | 1,194 | -766.95 | -5,327 | - | -3,641 | 4,857 | Upgrade
|
| Free Cash Flow Per Share | 7.49 | -4.27 | -30.96 | - | -30.78 | 41.06 | Upgrade
|
| Gross Margin | 37.34% | 35.14% | 39.89% | 100.00% | 41.21% | 43.66% | Upgrade
|
| Operating Margin | 6.20% | 2.37% | 3.64% | 0.35% | -0.63% | 0.37% | Upgrade
|
| Profit Margin | 5.37% | 1.30% | 2.30% | -1.98% | -4.21% | -5.27% | Upgrade
|
| Free Cash Flow Margin | 0.75% | -0.56% | -4.75% | - | -3.52% | 4.38% | Upgrade
|
| EBITDA | 14,483 | 7,895 | 8,057 | 4,176 | 2,794 | 3,847 | Upgrade
|
| EBITDA Margin | 9.12% | 5.73% | 7.19% | 3.59% | 2.70% | 3.47% | Upgrade
|
| D&A For EBITDA | 4,640 | 4,627 | 3,971 | 3,772 | 3,441 | 3,439 | Upgrade
|
| EBIT | 9,843 | 3,268 | 4,086 | 404.44 | -647.14 | 408.44 | Upgrade
|
| EBIT Margin | 6.20% | 2.37% | 3.64% | 0.35% | -0.63% | 0.37% | Upgrade
|
| Effective Tax Rate | 7.17% | 30.94% | 19.18% | - | - | - | Upgrade
|
| Advertising Expenses | - | - | - | - | 12,106 | 11,449 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.